RESUMO
Vaccines are among the greatest tools for prevention and control of disease. They have eliminated smallpox from the planet, decreased morbidity and mortality for major infectious diseases like polio, measles, mumps, and rubella, significantly blunted the impact of the COVID-19 pandemic, and prevented viral induced cancers such as cervical cancer caused by human papillomavirus. Recent technological advances, in genomics, structural biology, and human immunology have transformed vaccine development, enabling new technologies such as mRNA vaccines to greatly accelerate development of new and improved vaccines. In this review, we briefly highlight the history of vaccine development, and provide examples of where advances in genomics and structural biology, paved the way for development of vaccines for bacterial and viral diseases.
Assuntos
Biologia Molecular , Vacinas Virais , Viroses , Humanos , COVID-19/prevenção & controle , Biologia Molecular/história , Biologia Molecular/tendências , Pandemias , Viroses/história , Viroses/prevenção & controle , Vacinas Virais/históriaAssuntos
Vacinas contra COVID-19 , Vacinas Sintéticas , Vacinas Virais/história , Varíola Bovina/história , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Vacinas contra Poliovirus/história , Prevenção Primária , Vacina Antirrábica/história , Vacina Antivariólica/história , Vacinas de DNA , Vacina contra Febre Amarela/história , Vacinas de mRNAAssuntos
Betacoronavirus/patogenicidade , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Vacinas Virais/história , Alergia e Imunologia/história , COVID-19 , Vacinas contra COVID-19 , Infecções por Coronavirus/história , Infecções por Coronavirus/imunologia , Infecções por Coronavirus/virologia , História do Século XX , História do Século XXI , Humanos , Pneumonia Viral/imunologia , Pneumonia Viral/virologia , SARS-CoV-2 , Estados Unidos , Vacinas Virais/biossíntese , Virologia/históriaRESUMO
Chikungunya fever (CHIKF) is a mosquito-borne disease caused by Chikungunya virus (CHIKV). This virus is considered a priority pathogen to the UK government, the US National Institute of Allergy and Infectious Diseases (NIAID) and the US military personnel, due to the potential of CHIKV to cause major outbreaks. Nearly all CHIKV infections are symptomatic, often incapacitating and patients experience severe joint pain and inflammation that can last for more than one year with 0.4-0.5% fatality rates. Mother-to-child transmission has also been described. Despite this re-emerging disease has been documented in more than 100 countries in Europe, Oceania, Africa, Asia, the Caribbean, South and North America, no licensed vaccine is yet available to prevent CHIKF. Nevertheless, various developments have entered phase I and II trials and are now viable options to fight this incapacitating disease. This review focuses on the development of CHIKV vaccines that have reached the stage of clinical trials since the late 1960s up until 2018.
Assuntos
Febre de Chikungunya/prevenção & controle , Vírus Chikungunya/imunologia , Vacinas Virais/história , Animais , Ensaios Clínicos como Assunto , Modelos Animais de Doenças , Surtos de Doenças , História do Século XX , História do Século XXI , Humanos , Transmissão Vertical de Doenças Infecciosas , Vacinas Virais/imunologiaAssuntos
Infecções por Citomegalovirus/prevenção & controle , Desenvolvimento de Medicamentos/história , Poliomielite/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Vacinas Virais/história , Infecções por Citomegalovirus/virologia , História do Século XX , História do Século XXI , Humanos , Masculino , Poliomielite/virologia , Rubéola (Sarampo Alemão)/virologia , Virologia/história , Vírus/imunologiaAssuntos
Pesquisa Biomédica/história , Infecções por Rotavirus/história , Vacinas contra Rotavirus/administração & dosagem , Rotavirus , Vacinação/história , Feminino , História do Século XX , História do Século XXI , Humanos , Malaui , Infecções por Rotavirus/prevenção & controle , Vacinas contra Rotavirus/história , Vacinas Virais/históriaRESUMO
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment. As a biologically well-characterized mutant virus, MVA facilitates fundamental research to elucidate the functions of poxvirus host-interaction factors. As extremely safe viral vectors MVA vaccines have been found immunogenic and protective in various preclinical infection models. Multiple recombinant MVA currently undergo clinical testing for vaccination against human immunodeficiency viruses, Mycobacterium tuberculosis or Plasmodium falciparum. The versatility of the MVA vector vaccine platform is readily demonstrated by the swift development of experimental vaccines for immunization against emerging infections such as the Middle East Respiratory Syndrome. Recent advances include promising results from the clinical testing of recombinant MVA-producing antigens of highly pathogenic avian influenza virus H5N1 or Ebola virus. This review summarizes our current knowledge about MVA as a unique strain of vaccinia virus, and discusses the prospects of exploiting this virus as research tool in poxvirus biology or as safe viral vector vaccine to challenge existing and future bottlenecks in vaccinology.
Assuntos
Vetores Genéticos/genética , Vaccinia virus/genética , Vacinas Virais/imunologia , Viroses/prevenção & controle , Animais , Desenho de Fármacos , Vetores Genéticos/história , Vetores Genéticos/metabolismo , História do Século XX , História do Século XXI , Humanos , Vaccinia virus/metabolismo , Vacinas Virais/genética , Vacinas Virais/história , Viroses/virologiaRESUMO
The reports in 1993 that naked DNA encoding viral genes conferred protective immunity came as a surprise to most vaccinologists. This review analyses the expanding number of examples where plasmid DNA induces immune responses. Issues such as the type of immunity induced, mechanisms of immune protection, and how DNA vaccines compare with other approaches are emphasized. Additional issues discussed include the likely means by which DNA vaccines induce CTL, how the potency and type of immunity induced can be modified, and whether DNA vaccines represent a practical means of manipulating unwanted immune response occurring during immunoinflammatory diseases. It seems doubtful if DNA vaccines will replace currently effective vaccines, but they may prove useful for prophylactic use against some agents that at present lack an effective vaccine. DNA vaccines promise to be valuable to manipulate the immune response in situations where responses to agents are inappropriate or ineffective.
Assuntos
Imunogenicidade da Vacina/genética , Vacinação/métodos , Vacinas de DNA/imunologia , Vacinologia/tendências , Animais , Antígenos de Bactérias/genética , Antígenos de Bactérias/imunologia , Antígenos de Protozoários/genética , Antígenos de Protozoários/imunologia , Antígenos Virais/genética , Antígenos Virais/imunologia , Vacinas Bacterianas/genética , Vacinas Bacterianas/imunologia , Vetores Genéticos/genética , Vetores Genéticos/imunologia , História do Século XX , História do Século XXI , Humanos , Plasmídeos/genética , Plasmídeos/imunologia , Vacinas Protozoárias/genética , Vacinas Protozoárias/imunologia , Vacinação/tendências , Vacinas de DNA/genética , Vacinas de DNA/história , Vacinologia/história , Vacinas Virais/genética , Vacinas Virais/história , Vacinas Virais/imunologiaRESUMO
Porcine reproductive and respiratory syndrome (PRRS) caused by PRRS virus (PRRSV) was reported in the late 1980s. PRRS still is a huge economic concern to the global pig industry with a current annual loss estimated at one billion US dollars in North America alone. It has been 20 years since the first modified live-attenuated PRRSV vaccine (PRRSV-MLV) became commercially available. PRRSV-MLVs provide homologous protection and help in reducing shedding of heterologous viruses, but they do not completely protect pigs against heterologous field strains. There have been many advances in understanding the biology and ecology of PRRSV; however, the complexities of virus-host interaction and PRRSV vaccinology are not yet completely understood leaving a significant gap for improving breadth of immunity against diverse PRRS isolates. This review provides insights on immunization efforts using infectious PRRSV-based vaccines since the 1990s, beginning with live PRRSV immunization, development and commercialization of PRRSV-MLV, and strategies to overcome the deficiencies of PRRSV-MLV through use of replicating viral vectors expressing multiple PRRSV membrane proteins. Finally, powerful reverse genetics systems (infectious cDNA clones) generated from more than 20 PRRSV isolates of both genotypes 1 and 2 viruses have provided a great resource for exploring many innovative strategies to improve the safety and cross-protective efficacy of live PRRSV vaccines. Examples include vaccines with diminished ability to down-regulate the immune system, positive and negative marker vaccines, multivalent vaccines incorporating antigens from other porcine pathogens, vaccines that carry their own cytokine adjuvants, and chimeric vaccine viruses with the potential for broad cross-protection against heterologous strains. To combat this devastating pig disease in the future, evaluation and commercialization of such improved live PRRSV vaccines is a shared goal among PRRSV researchers, pork producers and biologics companies.
Assuntos
Síndrome Respiratória e Reprodutiva Suína/epidemiologia , Síndrome Respiratória e Reprodutiva Suína/prevenção & controle , Vírus da Síndrome Respiratória e Reprodutiva Suína/imunologia , Vacinas Virais/imunologia , Animais , Descoberta de Drogas/história , Descoberta de Drogas/tendências , História do Século XX , História do Século XXI , Síndrome Respiratória e Reprodutiva Suína/imunologia , Vírus da Síndrome Respiratória e Reprodutiva Suína/genética , Suínos , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/história , Vacinas Atenuadas/imunologia , Vacinas Virais/administração & dosagem , Vacinas Virais/históriaRESUMO
Live attenuated vaccines against human viral diseases have been amongst the most successful cost effective interventions in medical history. Smallpox was declared eradicated in 1980; poliomyelitis is nearing global eradication and measles has been controlled in most parts of the world. Vaccines function well for acute diseases such as these but chronic infections such as HIV are more challenging for reasons of both likely safety and probable efficacy. The derivation of the vaccines used has in general not been purely rational except in the sense that it has involved careful clinical trials of candidates and subsequent careful follow up in clinical use; the identification of the candidates is reviewed.
Assuntos
Vacinas Atenuadas/imunologia , Vacinas Atenuadas/isolamento & purificação , Vacinas Virais/imunologia , Vacinas Virais/isolamento & purificação , Viroses/prevenção & controle , Ensaios Clínicos como Assunto , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Vacinas Atenuadas/história , Vacinas Virais/história , Viroses/imunologiaRESUMO
This paper presents, from the perspective of technological development and production, the results of an investigation examining 61 clinical studies with vaccines conducted in Brazil between 1938-2013, with the participation of the Oswaldo Cruz Institute (IOC) and the Oswaldo Cruz Foundation (Fiocruz). These studies have been identified and reviewed according to criteria, such as the kind of vaccine (viral, bacterial, parasitic), their rationale, design and methodological strategies. The results indicate that IOC and Fiocruz have accumulated along this time significant knowledge and experience for the performance of studies in all clinical phases and are prepared for the development of new vaccines products and processes. We recommend national policy strategies to overcome existing regulatory and financing constraints.
Assuntos
Academias e Institutos/história , Vacinas Bacterianas/história , Ensaios Clínicos como Assunto/história , Vacinas Protozoárias/história , Vacinas Virais/história , Vacinas Bacterianas/uso terapêutico , Brasil , História do Século XX , História do Século XXI , Humanos , Vacinas Protozoárias/uso terapêutico , Pesquisa , Tecnologia Farmacêutica/métodos , Tecnologia Farmacêutica/tendências , Vacinas Virais/uso terapêuticoRESUMO
Vaccines have a history that started late in the 18th century. From the late 19th century, vaccines could be developed in the laboratory. However, in the 20th century, it became possible to develop vaccines based on immunologic markers. In the 21st century, molecular biology permits vaccine development that was not possible before.
Assuntos
Vacinação/história , Técnicas de Cultura de Células/história , Engenharia Genética/história , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Vírus Reordenados/genética , Vacinas Atenuadas/história , Vacinas de Produtos Inativados/história , Vacinas de Subunidades Antigênicas/história , Vacinas Virais/históriaRESUMO
This paper examines the successful campaign in Britain to develop canine distemper vaccine between 1922 and 1933. The campaign mobilized disparate groups around the common cause of using modern science to save the nation's dogs from a deadly disease. Spearheaded by landed patricians associated with the country journal The Field, and funded by dog owners and associations, it relied on collaborations with veterinary professionals, government scientists, the Medical Research Council (MRC) and the commercial pharmaceutical house the Burroughs Wellcome Company (BWC). The social organization of the campaign reveals a number of important, yet previously unexplored, features of interwar science and medicine in Britain. It depended on a patronage system that drew upon a large base of influential benefactors and public subscriptions. Coordinated by the Field Distemper Fund, this system was characterized by close relationships between landed elites and their social networks with senior science administrators and researchers. Relations between experts and non-experts were crucial, with high levels of public engagement in all aspects of research and vaccine development. At the same time, experimental and commercial research supported under the campaign saw dynamic interactions between animal and human medicine, which shaped the organization of the MRC's research programme and demonstrated the value of close collaboration between veterinary and medical science, with the dog as a shared object and resource. Finally, the campaign made possible the translation of 'laboratory' findings into field conditions and commercial products. Rather than a unidirectional process, translation involved negotiations over the very boundaries of the 'laboratory' and the 'field', and what constituted a viable vaccine. This paper suggests that historians reconsider standard historical accounts of the nature of patronage, the role of animals, and the interests of landed elites in interwar British science and medicine.
Assuntos
Pesquisa Biomédica/história , Vírus da Cinomose Canina/imunologia , Cinomose/história , Vacinas Virais/história , Animais , Ensaios Clínicos como Assunto/história , Comportamento Cooperativo , Cinomose/terapia , Cães , História do Século XX , Reino Unido , Vacinas Virais/imunologia , Vacinas Virais/uso terapêuticoAssuntos
Pesquisa Biomédica/história , Técnicas de Cultura de Células/história , Feto/citologia , Adulto , Pesquisa Biomédica/ética , Divisão Celular , Linhagem Celular , Senescência Celular , Criança , Feminino , Células HeLa , Declaração de Helsinki/história , História do Século XX , Humanos , Consentimento Livre e Esclarecido , Suécia , Obtenção de Tecidos e Órgãos/economia , Obtenção de Tecidos e Órgãos/ética , Estados Unidos , Vacinas Virais/história , Vacinas Virais/provisão & distribuiçãoRESUMO
The global eradication of rinderpest was declared in 2011. This is the second infectious disease to have been eradicated from the world after smallpox, for which eradication was declared in 1980. From a scientific aspect, smallpox eradication was achieved by improvements in the Jenner vaccine, originally developed in the 18th century. Developments in vaccine technology and virological techniques during the 20th century have contributed to the eradication of rinderpest. The scientific background to rinderpest eradication is briefly reviewed vis-à-vis that of smallpox eradication.
Assuntos
Doenças dos Bovinos/história , Doenças dos Bovinos/prevenção & controle , Vírus da Peste Bovina/imunologia , Peste Bovina/história , Peste Bovina/prevenção & controle , Vacinas Virais/história , Animais , Bovinos , Doenças dos Bovinos/imunologia , Doenças dos Bovinos/virologia , Erradicação de Doenças , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Peste Bovina/imunologia , Vacinas Virais/imunologiaRESUMO
In the early colonial history of South Africa, horses played an important role, both in general transportation and in military operations. Frequent epidemics of African horsesickness (AHS) in the 18th century therefore severely affected the economy. The first scientific research on the disease was carried out by Alexander Edington (1892), the first government bacteriologist of the Cape Colony, who resolved the existing confusion that reigned and established its identity as a separate disease. Bluetongue (BT) was described for the first time by Duncan Hutcheon in 1880, although it was probably always endemic in wild ruminants and only became a problem when highly susceptible Merino sheep were introduced to the Cape in the late 18th century. The filterability of the AHS virus (AHSV) was demonstrated in 1900 by M'Fadyean in London, and that of the BT virus (BTV) in 1905 by Theiler at Onderstepoort, thus proving the viral nature of both agents. Theiler developed the first vaccines for both diseases at Onderstepoort. Both vaccines consisted of infective blood followed by hyper-immune serum, and were used for many years. Subsequent breakthroughs include the adaptation to propagation and attenuation in embryonated eggs in the case of BTV and in mouse brains for AHSV. This was followed by the discovery of multiple serotypes of both viruses, the transmission of both by Culicoides midges and their eventual replication in cell cultures. Molecular studies led to the discovery of the segmented double-stranded RNA genomes, thus proving their genetic relationship and leading to their classification in a genus called Orbivirus. Further work included the molecular cloning of the genes of all the serotypes of both viruses and clarification of their relationship to the viral proteins, which led to much improved diagnostic techniques and eventually to the development of a recombinant vaccine, which unfortunately has so far been unsuitable for mass production.
Assuntos
Doença Equina Africana/história , Bluetongue/história , Orbivirus , Doença Equina Africana/epidemiologia , Doença Equina Africana/prevenção & controle , Doença Equina Africana/virologia , Animais , Bluetongue/epidemiologia , Bluetongue/prevenção & controle , Bluetongue/virologia , Ceratopogonidae/virologia , História do Século XVIII , História do Século XIX , História do Século XX , Cavalos , Insetos Vetores/virologia , Camundongos , Orbivirus/classificação , Orbivirus/fisiologia , Orbivirus/ultraestrutura , Ovinos , África do Sul/epidemiologia , Vacinas Virais/história , Vacinas Virais/imunologia , Cultura de Vírus/históriaRESUMO
In 2011, the 79th General Session of the World Assembly of the World Organisation for Animal Health (OIE) and the 37th Food and Agriculture Organization of the United Nations (FAD) Conference adopted a resolution declaring the world free from rinderpest and recommending follow-up measures to preserve the benefits of this new and hard-won situation. Eradication is an achievable objective for any livestock disease, provided that the epidemiology is uncomplicated and the necessary tools, resources and policies are available. Eradication at a national level inevitably reflects national priorities, whereas global eradication requires a level of international initiative and leadership to integrate these tools into a global framework, aimed first at suppressing transmission across all infected areas and concluding with a demonstration thatthis has been achieved. With a simple transmission chain and the environmental fragility of the virus, rinderpest has always been open to control and even eradication within a zoosanitary approach. However, in the post-1945 drive for more productive agriculture, national and global vaccination programmes became increasingly relevant and important. As rinderpest frequently spread from one region to another through trade-related livestock movements, the key to global eradication was to ensure that such vaccination programmes were carried out in a synchronised manner across all regions where the disease was endemic - an objective to which the European Union, the United States Agency for International Development, the International Atomic Energy Agency, the African Union-Interafrican Bureau of Animal Resources, FA0 and OIE fully subscribed. This article provides a review of rinderpest eradication, from the seminal work carried out by Giovanni Lancisi in the early 18th Century to the global declaration in 2011.